


OPTIMIZING TREATMENT IN PATIENTS WITH ROS1 REARRANGED NSCLC



Augtyro. Prescribing Information. Bristol-Myers Squibb. 2024. Accessed Jul 21, 2024.

https://packageinserts.bms.com/pi/pi_augtyro.pdf

Bergethon K, Shaw AT, Ou SH, et al. *ROS1* rearrangements define a unique molecular class of lung cancers. *J Clin Oncol*. 2012;30(8):863-870. doi:10.1200/JCO.2011.35.6345

Bi H, Ren D, Ding X, et al. Clinical characteristics of patients with *ROS1* gene rearrangement in non-small cell lung cancer: a meta-analysis. *Transl Cancer Res*. 2020;9(7):4383-4392. doi:10.21037/tcr-20-1813

Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in *ROS1* fusion-positive non-small-cell lung cancer. *N Engl J Med*. 2024;390(2):118-131. doi:10.1056/NEJMoa2302299

Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. *ROS1*-dependent cancers - biology, diagnostics and therapeutics. *Nat Rev Clin Oncol*. 2021;18(1):35-55. doi:10.1038/s41571-020-0408-9

Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in *ROS1* fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2020;21(2):261-270. doi:10.1016/S1470-2045(19)30690-4

Dugay F, Llamas-Gutierrez F, Gournay M, et al. Clinicopathological characteristics of *ROS1*- and *RET*-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. *Oncotarget*. 2017;8(32):53336-53351. doi:10.18632/oncotarget.18408

Girard N, Galland-Girodet S, Avrillon V, et al. Lorlatinib for advanced *ROS1*+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. *ESMO Open*. 2022;7(2):100418. doi:10.1016/j.esmoop.2022.100418

H. Lee Moffitt Cancer Center and Research Institute. Clinical trial of CD40L-augmented TIL for patients with EGFR, ALK, *ROS1*, or HER2-driven NSCLC. Last updated Mar 22, 2024. <https://clinicaltrials.gov/study/NCT05681780>

Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of *ROS1* rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. *Ann Oncol*. 2013;24(9):2364-2370. doi:10.1093/annonc/mdt220

Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring *ROS1* rearrangement. *J Clin Oncol*. 2017;35(23):2613-2618. doi:10.1200/JCO.2016.71.3701

Marchetti A, Barberis M, Di Lorito A, et al. *ROS1* gene fusion in advanced lung cancer in women: A systematic analysis, review of the literature, and diagnostic algorithm. *JCO Precis Oncol*. 2017;1:1-9. doi:10.1200/PO.16.00010

National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Published Nov 27, 2017. Accessed Jul 13, 2024.

https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf

National Comprehensive Cancer Network Guidelines. Non-Small Cell Lung Cancer. V7.2024. Published Jun 26, 2024.

https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Park S, Ahn BC, Lim SW, et al. Characteristics and outcome of *ROS1*-positive non-small cell lung cancer patients in routine clinical practice. *J Thorac Oncol*. 2018;13(9):1373-1382. doi:10.1016/j.jtho.2018.05.026

Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage IV *ROS1*-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. *J Thorac Oncol*. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.001

Rozlytrek. Prescribing Information. Genentech, Inc 2024. Accessed Jul 20, 2024. https://www.gene.com/download/pdf/rozlytrek_prescribing.pdf

Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in *ROS1*-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol*. 2019;30(7):1121-1126. doi:10.1093/annonc/mdz131

Takeuchi K, Soda M, Togashi Y, et al. RET, *ROS1* and ALK fusions in lung cancer. *Nat Med*. 2012;18(3):378-381. doi:10.1038/nm.2658

Xalkori. Prescribing information. Pfizer, Inc.; Sept 2023. Accessed Jul 21, 2024.

<https://labeling.pfizer.com/ShowLabeling.aspx?id=676>